C-Jun N-terminal kinase (JNK) isoforms play differing roles in otitis media

BMC Immunology

Allen F Ryan³  Stephen I Wasserman²  Nicholas Webster⁵  Kwang Pak¹  Jeffrey Pan⁴  Meredith Frie⁴  William Yao⁴ 

[1] Research Service, Veterans Administration Medical Center, San Diego 92151, CA, USA;Departments of Medicine/Allergy & Immunology, University of California, San Diego, La Jolla 92093, CA, USA;Surgery/Neuroscience, 0626, UCSD School of Medicine, 9500 Gilman Drive, La Jolla 92093-0626, CA, USA;Departments of Surgery/Otolaryngology, University of California, San Diego, La Jolla 92093, CA, USA;Departments of Medicine Endocrinology and Metabolism, University of California, San Diego, La Jolla 92093, CA, USA

关键词: Inflammation;    Tissue proliferation;    MAP kinase signaling;    Infection;    Nontypeable haemophilus influenzae;    Middle ear;   

Others  :  1077693
DOI  :  10.1186/s12865-014-0046-z

 received in 2014-02-12, accepted in 2014-10-02,  发布年份 2014

【 摘 要 】

Background

Innate immunity and tissue proliferation play important roles in otitis media (OM), the most common disease of childhood. CJUN terminal kinase (JNK) is potentially involved in both processes.

Results

Genes involved in both innate immune and growth factor activation of JNK are upregulated during OM, while expression of both positive and negative JNK regulatory genes is altered. When compared to wildtypes (WTs), C57BL/6 mice deficient in JNK1 exhibit enhanced mucosal thickening, with delayed recovery, enhanced neutrophil recruitment early in OM, and delayed bacterial clearance. In contrast, JNK2^−/− mice exhibit delayed mucosal hyperplasia that eventually exceeds that of WTs and is slow to recover, delayed recruitment of neutrophils, and failure of bacterial clearance.

Conclusions

The results suggest that JNK1 and JNK2 play primarily opposing roles in mucosal hyperplasia and neutrophil recruitment early in OM. However, both isoforms are required for the normal resolution of middle ear infection.

【 授权许可】

   
2014 Yao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Infante-Rivard C, Fernandez A: Otitis media in children: frequency, risk factors, and research avenues. Epidemiol Rev 1993, 15:444-465.
• [2]Klein JO: The burden of otitis media. Vaccine 2000, 1:S2-S8.
• [3]Melhus A, Ryan AF: A mouse model for acute otitis media. APMIS 2003, 111:989-111994.
• [4][http://www.who.int/pbd/deafness/activities/hearing_care/otitis_media.pdf] webcite World Health Organization: Chronic suppurative otitis media: burden of illness and management options..
• [5]Leibovitz E, Jacobs MR, Dagan R: Haemophilus influenzae: a significant pathogen in acute otitis media. Pediatr Infect Dis J 2004, 23:1142-1152.
• [6]Leichtle A, Lai Y, Wollenberg B, Wasserman SI, Ryan AF: Innate signaling in otitis media: pathogenesis and recovery. Curr Allergy Asthma Rep 2011, 11:78-84.
• [7]Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 2000, 103(2):239-252.
• [8]Potapova O, Gorospe M, Bost F, Dean NM, Gaarde WA, Holborrk NJ: c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J Biol Chem 2000, 275:24767-24775.
• [9]Lin A: Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays 2003, 25:17-24.
• [10]Haeusgen W, Herdegen T, Waetzig V: The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7. Eur J Cell Biol 2011, 90:536-544.
• [11]Karin M, Liu ZG, Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 1997, 9:240-246.
• [12]Foletta VC, Segal DH, Cohen DR: Transcriptional regulation in the immune system: all roads lead to AP-1. J Leukoc Biol 1998, 63:139-152.
• [13]Fanger GR, Johnson NL, Johnson GL: MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO J 1997, 16:4961-4972.
• [14]Xu Z, Kukekov NV, Greene LA: POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis. EMBO J 2003, 22:252-261.
• [15]Li X, Macleod R, Dunlop AJ, Edwards HV, Advant N, Gibson LC, Devine NM, Brown KM, Adams DR, Houslay MD, Baillie GS: A scanning peptide array approach uncovers association sites within the JNK/beta arrestin signalling complex. FEBS Lett 2009, 583:3310-3316.
• [16]Lattin J, Zidar DA, Schroder K, Kellie S, Hume DA, Sweet MJ: G-protein-coupled receptor expression, function, and signaling in macrophages. J Leukoc Biol 2007, 82:16-32.
• [17]Jeffrey KL, Camps M, Rommel C, Mackay CR: Targeting dual-specificity phosphatases: manipulating MAP kinase signaling and immune responses. Nat Rev Drug Discov 2007, 6:391-403.
• [18]Masuda K, Shima H, Watanabe M, Kikuchi K: MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein. J Biol Chem 2001, 276:39002-39011.
• [19]Ho DT, Bardwell AJ, Grewal S, Iverson C, Bardwell L: Interacting JNK-docking sites in MKK7 promote binding and activation of JNK mitogen-activated protein kinases. J Biol Chem 2006, 281:13169-13179.
• [20]Zama T, Aoki R, Kamimoto T, Inoue K, Ikeda Y, Hagiwara M: A novel dual specificity phosphatase SKRP1 interacts with the MAPK kinase MKK7 and inactivates the JNK MAPK pathway. Implication for the precise regulation of the particular MAPK pathway. J Biol Chem 2002, 277:23909-23918.
• [21]Hirsch DS, Pirone DM, Burbelo PD: A new family of Cdc42 effector proteins, CEPs, function in fibroblast and epithelial cell shape changes. J Biol Chem 2001, 276:875-883.
• [22]Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ: Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996, 15:2760-2770.
• [23]Furukawa M, Ebmeyer J, Ryan AF, Ebmeyer U, Sudhoff H, Broide D, Ryan AF, Wasserman S: Jun N-terminal protein kinase enhances middle ear mucosal proliferation during bacterial otitis media. Infect Immun 2007, 75:2562-2571.
• [24]Ryan AF, Ebmeyer J, Furukawa M, Pak K, Melhus A, Waserman SI, Chung WH: Mouse models of induced otitis media. Brain Res 2006, 1091:3-8.
• [25]Hsiao A, Ideker T, Olefsky JM, Subramaniam S: VAMPIRE microarray suite: a web based platform for the interpretation of gene expression data. Nucleic Acids Res 2005, 33:W627-W632.
• [26]Ebmeyer J, Furukawa M, Pak K, Ebmeyer U, Sudhoff H, Broide D, Ryan AF, Wasserman S: Role of mast cells in otitis media. J Allergy Clin Immunol 2005, 116:1129-1135.
• [27]Bogoyevitch MA, Kobe B: Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 2006, 70:1061-1095.
• [28]Leichtle A, Hernandez M, Ebmeyer J, Yamasaki K, Lai Y, Radek K, Choung YH, Euteneuer S, Pak K, Gallo R, Wasserman SI, Ryan AF: CC chemokine ligand 3 overcomes the bacteriocidal and phagocytic defect of macrophages and hastens recovery from experimental otitis media in TNF−/− mice. J Immunol 2010, 184:3087-3097.
• [29]Hernandez M, Leichtle A, Pak K, Ebmeyer J, Euteneuer S, Obonyo M, Guiney DG, Webster NJ, Broide DH, Ryan AF, Wasserman SI: Myeloid differentiation primary response gene 88 is required for the resolution of otitis media. J Infect Dis 2008, 198:1862-1869.
• [30]Triantafilou M, Triantafilou K: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002, 23:301-304.
• [31]Chiu R, Boyle WJ, Meek J, Smeal T, Huner T, Karin M: The c-Fos protein interacts with c-Jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell 1988, 54:541-552.
• [32]Levy CS, Slomiansky V, Gattelli A, Nahmod K, Pelisch F, Blaustein M, Srebrow A, Coso OA, Kordon EC: Tumor necrosis factor alpha induces LIF expression through ERK1/2 activation in mammary epithelial cells. J Cell Biochem 2010, 110:857-865.
• [33]Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 2002, 4:E131-E136.
• [34]van Dam H, Huguier S, Kooistra K, Baguet J, Vial E, van der Eb AJ, Herrlich P, Angel P, Castellazzi M: Autocrine growth and anchorage independence: two complementing Jun-controlled genetic programs of cellular transformation. Genes Dev 1998, 12(8):1227-1239.
• [35]Bode AM, Dong Z: The functional contrariety of JNK. Mol Carcinog 2007, 46:591-598.
• [36]Leppä S, Bohmann D: Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 1999, 18:6158-6162.
• [37]Kumar H, Kawai T, Akira S: Pathogen recognition by the innate immune system. Int Rev Immunol 2011, 30:16-34.
• [38]Palacios SD, Pak K, Kayali AG, Rivkin AZ, Aletsee C, Melhus A, Webster NJ, Ryan AF: Participation of Ras and extracellular regulated kinase in the hyperplastic response of middle-ear mucosa during bacterial otitis media. J Infect Dis 2002, 186:1761-1769.
• [39]Palacios SD, Pak K, Rivkin AZ, Kayali AG, Austen D, Aletsee C, Melhus A, Webster NJ, Ryan AF: Role of p38 mitogen-activated protein kinase in middle ear mucosa hyperplasia during bacterial otitis media. Infect Immun 2004, 72:4662-4667.
• [40]Brecht S, Kirchhof R, Chromik A, Willesen M, Nicolaus T, Raivich G, Wessig J, Waetzig V, Goetz M, Claussen M, Pearse D, Kuan CY, Vaudano E, Behrens A, Wagner E, Flavell RA, Davis RJ, Herdegen T: Specific pathophysiological functions of JNK isoforms in the brain. Eur J Neurosci 2005, 21:363-377.